One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel
doi : 10.1002/art.43287
EULAR/American College of Rheumatology Risk Stratification Criteria for Development of Rheumatoid Arthritis in the Risk Stage of Arthralgia
doi : 10.1002/art.43218
EULAR/American College of Rheumatology Classification Criteria for Pediatric Chronic Nonbacterial Osteomyelitis
doi : 10.1002/art.43137
Case-Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease
doi : 10.1002/art.43326
The Impact of Nonsteroidal Anti-Inflammatory Drugs on Radiographic Spinal Progression in Patients With Axial Spondyloarthritis: 10-Year Results From an Inception Cohort
doi : 10.1002/art.43447
Association of Abatacept With Lower Mortality Risk Compared to Rituximab in Rheumatoid Arthritis–Associated Interstitial Lung Disease: An Emulated Target Trial
doi : 10.1002/art.43332
Distinct HLA Associations for Antibody Multireactivity With Citrulline-Containing Type II Collagen Epitopes Versus More Limited Antibody Reactivity With Citrulline-Containing IgG Epitopes in Rheumatoid Arthritis
doi : 10.1002/art.43424
Gut Microbiota–Derived Tryptophan Indole Metabolites Ameliorate Collagen-Induced Arthritis in Mice Via Aryl Hydrocarbon Receptor Activation
doi : 10.1002/art.43430
ZBTB20 Regulating Postnatal Articular Cartilage Development and Homeostasis: Implications for Early-Onset Osteoarthritis
doi : 10.1002/art.43393
The Influence of Race, Ethnicity and Historical Redlining on Psoriatic Disease Burden and Clinical Outcomes
doi : 10.1002/art.43397
Glucagon-Like Peptide 1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases
doi : 10.1002/art.70044
Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients With Systemic Lupus Erythematosus and Lupus Nephritis
doi : 10.1002/art.43403
Podocyte Interleukin-23 Receptor Signaling in the Pathogenesis of Lupus Nephritis
doi : 10.1002/art.43395
Efficacy of Telitacicept in Childhood-Onset Systemic Lupus Erythematosus: A Prospective Multicenter Cohort Study With Inverse Probability of Treatment Weighting–Adjusted Comparison to a Historical Control Group Treated With Belimumab
doi : 10.1002/art.43417
The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis
doi : 10.1002/art.43398
Distinct Cancer Risk Profiles in Patients With Systemic Sclerosis With Autoantibody Stratification
doi : 10.1002/art.43339
Identification of Risk Factors for Incident Left Ventricular Systolic Dysfunction and Predictors of Cardiac Recovery in Patients With Systemic Sclerosis
doi : 10.1002/art.43408
Longitudinal Changes in Serum Urate Levels From Premenopause Through Postmenopause: Interrupted Time-Series Analyses
doi : 10.1002/art.43406
Diagnostic Implications and Correlates of Plasma Adenosine Deaminase 2 Activity and ADA2 Variants
doi : 10.1002/art.43412
Effect of Time to Start of Biologic Therapy on Treatment Response in Childhood Arthritis: Results From the UCAN CAN-DU Cohort
doi : 10.1002/art.43401
Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient-Reported Outcomes in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Withdrawal Trial
doi : 10.1002/art.43428
Clinical Images: Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome presenting as aseptic pustular dermatosis: A rare clinical manifestation
doi : 10.1002/art.43361
Clinical Images: Progressive calcinosis cutis universalis involving the intrapelvic muscles in systemic lupus erythematosus
doi : 10.1002/art.43368
Concordance between ultrasound and physical examination in enthesitis assessment: a call for further investigation: comment on the article by Di Matteo et al
doi : 10.1002/art.43148
JAK inhibitors did not increase the risk of major adverse cardiovascular events in patients with rheumatoid arthritis within the first two years of treatment: comment on the article by Aymon et al
doi : 10.1002/art.43369
Trimethoprim-sulfamethoxazole prophylaxis in antineutrophil cytoplasmic antibody-associated vasculitis: watch out for pseudoacute kidney injury. Comment on the article by Kim et al
doi : 10.1002/art.43373
“Negative� finding supports two-hit model: comment on the article by Kroese et al
doi : 10.1002/art.43385
Minimal tofacitinib dose for maintenance in axial spondyloarthritis: real-world data from a resource-limited setting
doi : 10.1002/art.43147
Less is more: hematologic safety and sustained efficacy of a modified low-dose etoposide regimen in macrophage activation syndrome
doi : 10.1002/art.43390
Correction to “Novel Genetic Loci in Early-Onset Gout Derived From Whole-Genome Sequencing of an Adolescent Gout Cohort�
doi : 10.1002/art.43178
Correction to “Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune Diseases�
doi : 10.1002/art.43181
